Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer. The collaboration agreement comes six weeks after Kite Pharma signed a $2.3 billion strategic partnership deal with Shoreline Biosciences for the development of off-the-shelf cell therapies.
Other articles
June 28, 2024
Freeflow Ventures Raises $90M In Funding For Early Stage Deep Tech Investments
Freeflow Ventures, announced today that it raised $50M in new funds through its…